GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Cash And Cash Equivalents

Bellerophon Therapeutics (Bellerophon Therapeutics) Cash And Cash Equivalents : $4.38 Mil (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Cash And Cash Equivalents?

Bellerophon Therapeutics's quarterly cash and cash equivalents declined from Mar. 2023 ($15.17 Mil) to Jun. 2023 ($10.58 Mil) but then stayed the same from Jun. 2023 ($10.58 Mil) to Sep. 2023 ($4.38 Mil).

Bellerophon Therapeutics's annual cash and cash equivalents declined from Dec. 2020 ($47.56 Mil) to Dec. 2021 ($24.74 Mil) and declined from Dec. 2021 ($24.74 Mil) to Dec. 2022 ($6.92 Mil).


Bellerophon Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Bellerophon Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Cash And Cash Equivalents Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.65 9.87 47.56 24.74 6.92

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.32 6.92 15.17 10.58 4.38

Bellerophon Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Bellerophon Therapeutics  (OTCPK:BLPH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Bellerophon Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines

From GuruFocus